Opna Bio's OPN-2853 (Zavabresib) granted Orphan Drug Designation for myelofibrosis by FDA, a BET inhibitor.
In South San Francisco, Opna Bio, a clinical-stage biopharmaceutical company specializing in oncology therapeutics, has revealed that its Bet small molecule inhibitor, OPN-2853, has received Orphan Drug Designation from the FDA for the management of myelofibrosis. The generic name "zavabresib" has also been accepted internationally. This designation provides various benefits to assist in the development and commercialization of OPN-2853 for treating myelofibrosis, a condition affecting a specific number of people in the US.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments